Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Osteoclasts in Bone Remodeling01:31

Osteoclasts in Bone Remodeling

Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during bone...
Bone Remodeling01:40

Bone Remodeling

Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.
Bone Disorders01:29

Bone Disorders

Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Hormones and Bone Tissue01:17

Hormones and Bone Tissue

The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
Phosphoinositides and PIPs01:42

Phosphoinositides and PIPs

Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cost-savings from fracture prevention with zoledronate in randomised controlled trials.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·2026
Same author

Management of Postmenopausal Osteoporosis.

Endocrine reviews·2026
Same author

Decreased Nonvertebral Fracture Incidence with Zoledronate Use For >3 Years: Post Hoc Analysis of an RCT.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·2026
Same author

Antifracture Efficacy of 5- or 10-Yearly Zoledronate in Women Aged 50 to 60 Years: Secondary Analyses of a Randomized Trial.

The Journal of clinical endocrinology and metabolism·2025
Same author

Editorial commentary: Calcium/Vitamin D supplements and the heart.

Trends in cardiovascular medicine·2025
Same author

Development of fatty acid analogues with potent anabolic effects on bone in male mice.

Bone reports·2025
Same journal

Baseline β-CTX and BMI predict suitability for deferred zoledronic acid redosing beyond 12 months in postmenopausal Indian women with osteoporosis.

Bone·2026
Same journal

Bone density-based maturation of the midpalatal suture in children aged 8-15 years.

Bone·2026
Same journal

Disrupted phosphate metabolism and SIBLING/ASARM peptide accumulation underlie impaired bone mineralization in klotho-deficient (kl/kl) mice.

Bone·2026
Same journal

Linking genetic variants to bone microstructure: Histological signatures of osteogenesis imperfecta subtypes.

Bone·2026
Same journal

The impact of alcohol consumption on bone mineral density: Insights from cross-sectional and Mendelian randomization studies.

Bone·2026
Same journal

Systemic and local predictors of medication-related osteonecrosis of the jaw in patients receiving antiresorptive therapy: The Shizuoka Kokuho Database study.

Bone·2026
See all related articles

Related Experiment Videos

Bisphosphonates in Paget's disease.

Ian R Reid1, D J Hosking

  • 1Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, New Zealand. i.reid@auckland.ac.nz

Bone
|September 14, 2010
PubMed
Summary
This summary is machine-generated.

Bisphosphonates have evolved significantly for treating Paget's disease, a high turnover bone condition. Newer potent drugs like zoledronic acid now offer long-term remission possibilities previously unattainable.

Related Experiment Videos

Area of Science:

  • Bone Metabolism and Endocrinology
  • Pharmacology and Therapeutics

Background:

  • Paget's disease is a common metabolic bone disorder characterized by high bone turnover.
  • Early bisphosphonate therapies for Paget's disease presented therapeutic challenges due to suboptimal drug profiles.

Purpose of the Study:

  • To review the historical development and efficacy of bisphosphonates in treating Paget's disease.
  • To highlight the advancements in bisphosphonate potency and their impact on treatment outcomes.

Main Methods:

  • Literature review of early bisphosphonate use in Paget's disease.
  • Analysis of the evolution of bisphosphonate potency over decades.
  • Examination of the clinical impact of intravenous zoledronic acid.

Main Results:

  • Initial bisphosphonates identified key therapeutic principles but were limited by lower potency.
  • Progressive increases in bisphosphonate potency have been achieved over time.
  • Intravenous zoledronic acid demonstrates the capacity for inducing sustained long-term remissions in Paget's disease.

Conclusions:

  • The treatment of Paget's disease has been revolutionized by advancements in bisphosphonate therapy.
  • Modern potent bisphosphonates, such as zoledronic acid, offer unprecedented long-term disease control.